Title : Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia.

Pub. Date : 2016 Dec 14

PMID : 27983649






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sixteen novel epidermal growth factor receptor (EGFR)/vascular endothelial growth factor (VEGF)-2 inhibitors (nitroimidazole-substituted 4-anilinoquinazoline derivatives (16a-p)) were designed and prepared via the introduction of a nitroimidazole group in the piperidine side chain and modification on the aniline moiety of vandetanib. vandetanib epidermal growth factor receptor Homo sapiens
2 Preliminary biological tests showed that comparing with vandetanib, some target compounds exhibited excellent EGFR inhibitory activities and anti-proliferative over A549/H446 cells in hypoxia. vandetanib epidermal growth factor receptor Homo sapiens